Consistency and Applicability of Studies on Breast Cancer: A Literature Summary Table

This literature summary table rates the quality of individual studies on breast cancer and groups papers by research question and intervention strategies examined. It examines the consistency and applicability of studies, and provides strategies for effective breast cancer diagnosis, early detection, and treatment. The table also identifies Ottawa Charter Action Areas relevant to each strategy.

TASK 1 C LITERATURE SUMMARY TABLE TEMPLATE.
Health issue: Breast Cancer
Student:
Group papers by research question
and intervention strategies examined
Rate quality of
individual studies
1 _______________ 5
Scale: 1 (poor) to 5
(excellent)
Decide on consistency
among good quality
studies
1 _______________ 5
Scale: 1 to 5
1 (findings are inconsistent)
5 (findings are highly
consistent)
Decide on applicability
of the consistent
findings
Responses:
 Applicable
 Possibly applicable
 Not applicable
Strategy:
 Effective international
agreement between the
health nutrition leaders,.
 Support through grant
and conference.
OC Action Areas: BHPP, Articles 1-6
Good- 3
Average-1, 4-6
Poor- 2
1,2,4-6- Consistent
3- Excellent
Applicable- 3
Possibly applicable-
1,2,4,6
Strategy:
 Diagnosis for firstdegree
relatives in case of breast
cancer.
 Using biomarkers such as
BRCA1, BRCA2 and TP53
for early detection.
 Using point mutation of
BRCA1.
 Sentinel
lymphodenectomy to
identify the tumour free
auxillary nodes in case of
breast cancer.
OC Action Areas: CSE, Articles7-10
Good- 10
Average-7,9
Poor- 8
7-Consistent
8- Inconsistent
9-Well written
10- Well structured
Applicable- 7,10
Possibly applicable-
9
Not applicable- 8
Strategy:
 Adjuvant systematic
therapy.
 Using muldidisciplinary
team approaches.
 Promote breast self-
examination to create
awareness.
OC Action Areas: SCA Articles 11-14
Average-11, 13, 14
Poor- 12
11- Clearly defined and
consistent.
12- Non-consistent
13- Well consistent.
14- Consistent, but
need clear idea to be
incorporated
Applicable- 11,13
Possibly applicable-
14
Not applicable- 12
Strategy:
 Pre-operative
chemotherapy.
 Hormone replacement
therapy.
 Using sequential paclitaxel
Good- 15-20 15- 20- Consistent, wel
structured and
explained clearly.
Applicable- 15-20

in adjuvantchemotherapy.
 Using Anastrozole in
combination with
Tamoxifen.
 Neoadjuvant
chemotherapy.
OC Action Areas: RHS, Articles 15-20
LEGEND
Ottawa Charter Action Areas:
BHPP Build healthy public policy
CSE Create supportive
environments
SCA Strengthen community action]
DPS Develop personal skills
RHS Reorient (health) services

References:
1. Hughes R. Definitions for public health nutrition: a developing consensus. Public Health Nutrition.
2003 Sep;6(6):615-20.
2. Dohnt HK, Tiggemann M. Body image concerns in young girls: The role of peers and media prior to
adolescence. Journal of youth and adolescence. 2006 Apr 1;35(2):135.
3. World Health Organization. Ottawa charter for health promotion. Health promotion. 1986;1:iii-v.
4. Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, Carlson RW, Azavedo E, Harford J.
Guideline implementation for breast healthcare in low income and middle income countries. Cancer.‐ ‐
2008 Oct 15;113(S8):2221-43.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative
reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast
cancer and 101 986 women without the disease. The Lancet. 2001 Oct 27;358(9291):1389-99.
6. De Bock GH, Bonnema J, van Der Hage J, Kievit J, Van de Velde CJ. Effectiveness of routine visits and
routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive
breast cancer: a meta-analysis and systematic review. Journal of Clinical Oncology. 2004 Oct
1;22(19):4010-8.
7. Lalloo F, Evans DG. Familial breast cancer. Clinical genetics. 2012 Aug;82(2):105-14.
8. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O,
Borg Å, Pasini B. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2
mutations detected in case series unselected for family history: a combined analysis of 22 studies. The
American Journal of Human Genetics. 2003 May 1;72(5):1117-30.
9. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and
obesity as risk factors for breast cancer: associations and interactions in an international case control‐
study. International journal of cancer. 1990 Nov 15;46(5):796-800.
10. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC, Turner RR. Prospective
observational study of sentinel lymphadenectomy without further axillary dissection in patients with
sentinel node–negative breast cancer. Journal of Clinical Oncology. 2000 Jul 1;18(13):2553-9.
11. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy.
Analysis of 716 consecutive patients. Cancer. 1978 Mar;41(3):1170-8.
12. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer:
progress and controversy. CA: a cancer journal for clinicians. 1995 Jul;45(4):199-226.
13. Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki BJ, Rosato EF, Lawton T, Conant EF, Orel SG,
Schuchter L, Fox KR. The impact of a multidisciplinary breast cancer center on recommendations for
patient management: the University of Pennsylvania experience. Cancer. 2001 Apr 1;91(7):1231-7.
14. McCready T, Littlewood D, Jenkinson J. Breast self examination and breast awareness: a literature‐
review. Journal of Clinical Nursing. 2005 May;14(5):570-8.
15. Ritte R, Lukanova A, Berrino F, Dossus L, Tjønneland A, Olsen A, Overvad TF, Overvad K, Clavel-
Chapelon F, Fournier A, Fagherazzi G. Adiposity, hormone replacement therapy use and breast cancer
risk by age and hormone receptor status: a large prospective cohort study. Breast cancer research.
2012 Jun;14(3):R76.
16. NIH consensus conference. Treatment of early-stage breast cancer. JAMA. 1991; 265: 391-395.
17. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL,
Vogel VG, Dakhil SR, Tamkus D. Preoperative chemotherapy: updates of national surgical adjuvant
breast and bowel project protocols B-18 and B-27. Journal of Clinical Oncology. 2008 Feb
10;26(5):778-85.
18. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR,
Hayes DF, Tkaczuk KH, Fleming G. Improved outcomes from adding sequential paclitaxel but not from
escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive
primary breast cancer. Journal of clinical oncology. 2003 Mar 15;21(6):976-83.

19. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. Anastrozole alone or in
combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal
women with early breast cancer: first results of the ATAC randomised trial. Lancet (London, England).
2002 Jun;359(9324):2131-9.
20. Meyers MO, Klauber-DeMore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC,
Carey LA. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated
with neoadjuvant chemotherapy for locally advanced breast cancer. Annals of surgical oncology. 2011
Oct 1;18(10):2851-7.